|
WO2021021837A2
|
|
Anti-pvrig antibodies formulations and uses thereof
|
|
AU2019276578A1
|
|
Anti-PVRIG/anti-TIGIT bispecific antibodies and methods of use
|
|
US2020002416A1
|
|
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
US2019309044A1
|
|
Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
|
|
US2020270343A1
|
|
Anti-vsig10 antibodies and methods of use
|
|
AU2018276140A1
|
|
Triple combination antibody therapies
|
|
IL256261D0
|
|
Hide1 compositions and methods
|
|
CN110088132A
|
|
Anti- TIGIT antibody, anti-PVRIG antibody and combinations thereof
|
|
WO2017066714A1
|
|
Anti-vsig1 antibodies and drug conjugates
|
|
EP3322733A1
|
|
Hide1 compositions and methods
|
|
US2017088607A1
|
|
PVRIG polypeptides and methods of treatment
|
|
WO2016134333A1
|
|
Anti-pvrig antibodies and methods of use
|
|
AU2015275292A1
|
|
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
EP3185885A1
|
|
Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
|
|
IL239188D0
|
|
Methods for predicting hepatotoxicity
|
|
CA2922805A1
|
|
Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
|
|
WO2015037000A1
|
|
Vstm5 polypeptides and uses thereof for treatment of cancer, infectious diseases and immune related diseases
|
|
JP2014240384A
|
|
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
AU2014201027A1
|
|
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
KR20150023811A
|
|
Lsr antibodies, and uses thereof for treatment of cancer
|
